News

Notice of Interim Results and Analyst / Investor Event

London, UK, 26 August 2022: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its interim results for the six months ended 30 June 2022 on 27 September 2022.

On the same day, the Company will be holding an analyst and investor event, including an overview of its interim results, in London from 14:00 BST (09:00 ET). The event will also be accessible via webcast and a recording of the presentation will be made available on the Company’s website afterwards.

To register your interest in attending either in person or virtually, please contact FTI Consulting at BenevolentAI@fticonsulting.com or +44 (0) 20 3727 1000.


About BenevolentAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The Benevolent Platform™ powers a growing in-house pipeline of over 20 disease programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Contacts for BenevolentAI

Media:

Rajin King – VP Communications

rajin.kang@benevolent.ai

Investors:

Fleur Wood – VP Investor Relations

investors@benevolent.ai

fleur.wood@benevolent.ai

FTI Consulting:

Ben Atwell, Simon Conway, Victoria Foster Mitchell

BenevolentAI@fticonsulting.com 

+44 (0) 20 3727 1000

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
BenevolentAI appoints GSK drug discovery veteran Dr Nicola Richmond as Vice President of AI
As VP of AI, Dr Nicola Richmond will be responsible for spearheading BenevolentAI’s AI strategy and working to ensure the Company maintains its leading position in AI-enabled drug discovery.
Jul 6, 2022